

MCG 012-01

EV 032 196 839 US

PATENT

RECEIVED

NOV 14 2002

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of : M. Vijay Kumar
Serial No. : 10/077,435
Filing Date : February 15, 2002
Title : TREATMENT OF PROSTATE CANCER
Examiner : Unassigned
Group Art Unit : 1614

Assistant Commissioner of Patents
Washington, DC 20231

Sir:

INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached Form PTO/SB/08A. A copy of each of the one-hundred thirty-three (133) references listed on the attached form is submitted herewith. Applicants respectfully request that the references listed on the attached form be expressly considered by the Examiner and be made of record in the application and appear among the "References Cited" on any patent to issue therefrom. In so doing, Applicants do not waive any rights to appropriate action to establish patentability over the listed documents should they be applied as references against the claims of the present application. This Information Disclosure Statement should not be construed as a representation that more material information does not exist or that a search of the relevant art has been made.

This Information Disclosure Statement is being submitted prior to the mailing of a first action on the merits in the present application. Accordingly, it is believed that no fees are due for consideration of this Information Disclosure Statement. However, should any fees be due, the Assistant Commissioner is authorized to charge such fees to Deposit Account 16-1435. A duplicate of this sheet is attached for that purpose.

Respectfully submitted,

Cynthia B. Rothschild, Reg. No. 47,040

Date: November 12, 2002

KILPATRICK STOCKTON LLP
1001 West Fourth Street
Winston-Salem, North Carolina 27101-2400
(336) 747-7541 Phone
(336) 607-7500 Facsimile
Attorney Docket No.: M0351-268908
M0351-268908
WINLIB01:957113.1

+

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Compleat if Known

(use as many sheets as necessary)

Sheet	1	of	9
-------	---	----	---

Application Number	10/077,435
Filing Date	February 15, 2002
First Named Inventor	M. Vijay Kumar
Group Art Unit	1614
Examiner Name	Unassigned
Attorney Docket Number	M0351-268908 (012-01)
Express Mail Certificate	EV 032 196 839 US

[illegible][illegible]

Date Considered

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231.

Please type a plus sign (+) inside this box → +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449APTO



Complete if Known

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 9

Application Number 10/077,435
Filing Date February 15, 2002
First Named Inventor M. Vijay Kumar
Group Art Unit 1614
Examiner Name Unassigned
Attorney Docket Number M0351-268908
Express Mail Certificate EV 032 196 839 US



OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	2	ASHKENAZI, A. et al., Death receptors: Signaling and modulation, <i>Science</i> , 281 , 1305-1308, 1998	✓
	3	ASHKENAZI, A. et al., Safety and antitumor activity of recombinant soluble Apo2 ligand, <i>J. Clin. Invest.</i> , 104 , 155-162, 1999	✓
	4	BEG, A. A. et al., An essential role for NF-κB in preventing TNF-α-induced cell death, <i>Science</i> , 274 , 782-784, 1996	✓
	5	BEIER, H. M. et al., Modification of endometrial cell biology using progesterone antagonists to manipulate the implantation window, <i>Human Reproduction</i> , 9 , 98-115, 1994	✓
	6	BERNARD, D. et al., Rel/NF-κB transcription factors protect against tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by up-regulating the TRAIL decoy receptor DcR1, <i>J. Biol. Chem.</i> , 276 , 27322-27328, 2001	✓
	7	BIELINSKA, A. et al., Regulation of gene expression with double-stranded phosphorothioate oligonucleotides, <i>Science</i> , 250 , 997-999, 1990	✓
	8	BOSSY-WETZEL, E. et al., Caspases induce cytochrome c release from mitochondria by activating cytosolic factors, <i>J. Biol. Chem.</i> , 274 , 17484-17490, 1999	✓
	9	BOUT, Abraham et al., Lung Gene Therapy: <i>In Vivo</i> adenovirus-mediated gene transfer to rhesus monkey airway epithelium, <i>Human Gene Therapy</i> , 5 , 3-10, 1994	✓
	10	BOWEN, C. et al., Synthesis of procaspases-3 and -7 during apoptosis in prostate cancer cells, <i>Cell Death & Diff.</i> , 6 , 394-401, 1999	✓
	11	BRUCKHEIMER, E. M. et al., Implications of cell death regulation in the pathogenesis and treatment of prostate cancer, <i>Sem. Oncol.</i> , 26 , 382-398, 1999	✓
	12	BUTTYAN, R. et al., Anti-apoptosis genes and the development of hormone-resistant prostate cancer, In: <i>Prostate – Basic and Clinical Aspects</i> , pp 201-218, Naz RK (ed), CRC Press, Boca Raton, 1997	✓
	13	CARSON, J. P. et al., Antiapoptotic signaling in LNCaP prostate cancer cells: a survival signaling pathway independent of phosphatidylinositol 3-kinase and Akt/protein kinase B, <i>Cancer Res.</i> , 59 , 1449-1453, 1999	✓
	14	CHAUDARY, P. M. et al., Death receptor 5, a new member of the TNFR family, and DR4 induce FADD-dependent apoptosis and activate the NF-κB pathway, <i>Immunity</i> , 7 , 821-830, 1996	✓
	15	CHU, Z-L. et al., Suppression of tumor necrosis factor-induced cell death by inhibitor of apoptosis c-IAP2 is under NF-κB control, <i>Proc. Natl. Acad. Sci., USA</i> , 94 , 10057-10062, 1997	✓
	16	COLOMBEL, M. C. et al., Hormonal control of apoptosis: The rat prostate gland as a model system, <i>Methods Cell. Biol.</i> , 46 , 369-385, 1995	✓
	17	DAI, D. et al., Regression of the decidualized mesometrium and decidual cell apoptosis are associated with a shift in expression of Bcl2 family members, <i>Biol. Reprod.</i> , 63 , 188-195, 2000	✓

Please type a plus sign (+) inside this box → +

PTO/SB/OBA (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449APTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)


Sheet **3** of **9**

Complete if Known

Applicati n Number	10/077,435
Filing Date	February 15, 2002
First Named Inventor	M. Vijay Kumar
Group Art Unit	1614
Examiner Name	Unassigned
Attorney Docket Number	M0351-268908
Express Mail Certificate	EV 032 196 839 US

TECH CENTER 1000/2900
NOV 14 2002

RECEIVED



18	DAI, J. L. et al., Androgenic up-regulation of androgen receptor cDNA expression in androgen-independent prostate cancer cells, <i>Steroids</i> , 61 , 531-539, 1996	✓
19	De VERE WHITE, R. et al., Human androgen receptor expression in prostate cancer following androgen ablation, <i>Eur. Urol.</i> , 31 , 1-6, 1997	✓
20	DEGLI-Esposito et al., The novel receptor TRAIL-R4 induces NF-κB and protects against TRAIL mediated apoptosis, yet retains an incomplete death domain, <i>Immunity</i> , 7 , 813-820, 1997	✓
21	DENMEADE, S. R., et al., Inhibition of caspase activity does not prevent the signaling phase of apoptosis in prostate cancer cells, <i>Prostate</i> , 39 , 269-279, 1999	✓
22	ECK, S. L.. et al., Inhibition of phorbol ester-induced cellular adhesion by competitive binding of NF-κB in vivo, <i>Mol. Cell. Biol.</i> , 13 , 6530-6536, 1993	✓
23	EGGERT, A. et al., Resistance to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in neuroblastoma cells correlates with a loss of caspase-8 expression, <i>Cancer Res.</i> , 61 , 1314-1319, 2001	✓
24	EKMAN, P. et al., Steroid receptors in metastatic carcinoma of the human prostate, <i>Eur. J. Cancer</i> , 15 , 257-262, 1979	✓
25	EL ETREBY, M. F. et al., Effect of antiprogestins and tamoxifen on growth inhibition of MCF-7 human breast cancer cells in nude mice, <i>Breast Can. Res. Treat.</i> , 49 , 109-117, 1998	✓
26	EL ETREBY, M. F. et al., Additive effect of mifepristone and tamoxifen on apoptotic pathways in MCF-7 human breast cancer cells, <i>Breast Can. Res. Treat.</i> , 51 , 149-168, 1998	✓
27	EL ETREBY, M. F. et al., Induction of apoptosis by mifepristone and tamoxifen in human LNCaP prostate cancer cells in culture, <i>Prostate</i> , 43 , 31-42, 2000	✓
28	EL ETREBY, M. F. et al., Antitumor activity of mifepristone in the human LNCaP, LNCaP-C4 and LNCaP-C4-2 prostate cancer models in nude mice, <i>Prostate</i> , 42 , 99-106, 2000	✓
29	ERL, W. et al., Nuclear factor-κB regulates induction of apoptosis and inhibitor of apoptosis protein-1 expression in vascular smooth muscle cells, <i>Circ. Res.</i> , 84 , 668-677, 1999	✓
30	ESKES, R. et al., Bid induces the oligomerization and insertion of Bax into the outer mitochondrial membrane, <i>Mol. Cell. Biol.</i> , 20 , 929-935, 2000	✓
31	FRENCH, L. et al., Inhibition of death receptor signaling by FLICE-inhibitory protein as a mechanism for immune escape of tumors, <i>J. Exp. Med.</i> , 190 , 891-893, 1999	✓
32	GIBSON, S. B. et al., Increased expression of death receptors 4 and 5 synergizes the apoptosis response to combined treatment with etoposide and TRAIL, <i>Mol. Cell. Biol.</i> , 20 , 205-212, 2000	✓
33	GOLDRING, C.E.P. et al., Transcriptional inhibition of the inducible nitric oxide synthase gene by competitive binding of NFκB/REL proteins, <i>Biochem. Biophys. Res. Comm.</i> , 209 , 73-79, 1995	✓
34	GOMEZ-FOIX, Adenovirus-mediated transfer of the muscle glycogen phosphorylas gene into hepatocytes confers altered regulation of glycogen metabolism, <i>J. Biol. Chem.</i> , 267 , 25129-25134, 1992	✓

Please type a plus sign (+) inside this box → ☐

PTO/SB/Q8A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449APTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 4 of 9

Complete if Known

Application Number	10/077,435
Filing Date	February 15, 2002
First Named Inventor	M. Vijay Kumar
Group Art Unit	1614
Examiner Name	Unassigned
Attorney Docket Number	M0351-268908
Express Mail Certificate	EV 032 196 839 US

TECH CENTER 1600/2900
NOV 14 2002

RECEIVED

35	GREGORY, C. W. et al., Androgen receptor expression in androgen-independent prostate cancer is associated with increased expression of androgen-regulated genes, <i>Cancer Res.</i> , 58 , 5718-5724, 1998	✓
36	GREGORY, C. W. et al., Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen, <i>Cancer Res.</i> , 61 , 2892-2898, 2001	✓
37	GROSS, A. et al., Caspase cleaved BID targets mitochondria and is required by cytochrome c release, while BCL-X _L prevents this release but not tumor necrosis factor-R1/Fas death, <i>J. Biol. Chem.</i> , 274 , 1156-1163, 1999	✓
38	GUO, Y. et al., Restoration of transforming growth factor-β signaling pathway in human prostate cancer cells suppresses tumorigenicity via induction of caspase-1 mediated apoptosis, <i>Cancer Res.</i> , 59 , 1366-1371, 1999	✓
39	GUZMANN, et al., Efficient gene transfer into myocardium by direct injection of adenovirus vectors, <i>Circulation Res.</i> , 73 , 1202-1207, 1993	✓
40	HAO, C. et al., Induction and intracellular regulation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) mediated apoptosis in human malignant glioma cells, <i>Cancer Res.</i> , 61 , 1162-1170, 2001	✓
41	HEISLER, L. E. et al., Androgen-dependent cell cycle arrest and apoptotic death in PC-3 prostatic cell cultures expressing a full-length human androgen receptor, <i>Mol. Cell. Endocr.</i> , 126 , 59-73, 1997	✓
42	HENGARTNER, M. O., The biochemistry of apoptosis, <i>Nature</i> , 407 , 770-776, 2000	✓
43	HOLCİK, M. et al., XIAP, the guardian angel, <i>Nature Rev. Mol. Cell Biol.</i> , 2 , 550-556, 2001	✓
44	HU, W-H. et al., Activation of NF-κB by FADD, Casper, and Caspase-8, <i>J. Biol. Chem.</i> , 275 , 10838-10844, 2000	✓
45	JOLY-PHARABOZ, M. O. et al., Androgens inhibit the proliferation of a variant of the human prostate cancer cell line LNCaP, <i>J. Steroid Biochem. Mol. Biol.</i> , 55 , 67-76, 1995	✓
46	JOLY-PHARABOZ, M. O. et al., Inhibition of growth and induction of apoptosis by androgens of a variant of LNCaP cell line, <i>J. Steroid Biochem. Mol. Biol.</i> , 73 , 237-249, 2000	✓
47	JONES, D. R. et al., Inhibition of NF-κB sensitizes non-small cell lung cancer cells to chemotherapy-induced apoptosis, <i>Ann. Thoracic Surg.</i> , 70 , 930-937, 2000	✓
48	KAMRADT, J. M. et al., Novel molecular targets for prostate cancer therapy, <i>Seminars Oncol.</i> , 26 , 234-243, 1999	✓
49	KAMRADT, M. C. et al., RU 486 increases radiosensitivity and restores apoptosis through modulation of HPV E6/E7 in dexamethasone-treated cervical carcinoma cells, <i>Gynecol. Oncol.</i> , 77 , 177-182, 2000	✓
50	KANEGAE, Y. et al., Role of Rel/NF-κB transcription factors during the outgrowth of the vertebrate limb, <i>Nature</i> , 392 , 611-614, 1998	✓
51	KAUFMAN, S. H. et al., Apoptosis in cancer: cause and cure, <i>Bio Essays</i> , 22 , 1007-1017, 2000	✓
52	KIMURA, K. et al., Androgen blocks apoptosis of hormone dependent prostate cancer cells, <i>Cancer Res.</i> , 61 , 5611-5618, 2001	✓

Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number



RECEIVED
NOV 14 2002
TECH CENTER 1600/2900

Substitute for form 1449APTO

Complete if Known


**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 5 of 9

Application Number	10/077,435
Filing Date	February 15, 2002
First Named Inventor	M. Vijay Kumar
Group Art Unit	1614
Examiner Name	Unassigned
Attorney Docket Number	M0351-268908
Express Mail Certificate	EV 032 196 839 US

53	KOIDE, S. S., Mifeprisone: Auxiliary therapeutic use in cancer and related disorders, <i>J. Reprod. Med.</i> , 43 , 551-560, 1998	✓
54	KONTNY, H. U. et al., Sensitivity of Ewing's sarcoma to TRAIL-induced apoptosis, <i>Cell Death & Diff.</i> , 8 , 506-514, 2001	✓
55	KORSMEYER, S. J. et al., Pro-apoptotic cascade activates BID, which oligomerizes BAK or BAX into pores that result in the release of cytochrome c, <i>Cell Death Diff.</i> , 7 , 1166-1173, 2000	✓
56	KOZLOWSKI, J. et al., Advanced prostatic carcinoma: Early vs. late endocrine therapy, <i>Urol. Clin. N. Am.</i> , 18 , 15-24, 1991	✓
57	KREIS, W., Current chemotherapy and future directions in research for the treatment of advanced hormone-refractory prostate cancer, <i>Cancer Invest.</i> , 13 , 296-312, 1995	✓
58	KUWANO, K. et al., Signal transduction pathways of apoptosis and inflammation induced by the tumor necrosis factor receptor family, <i>Am. J. Respir. Cell Mol. Biol.</i> , 22 , 147-149, 2000	✓
59	KYPRIANOU, N. et al., Thymine-less death in androgen-independent prostate cancer cells, <i>Biochem. Biophys. Res. Comm.</i> , 165 , 73-81, 1989	✓
60	KYPRIANOU, N. et al., Apoptosis: Therapeutic significance in the treatment of androgen-dependent and androgen-independent prostate cancer, <i>World J. Urol.</i> , 12 , 299-303, 1994	✓
61	La SALLE, An adenovirus vector for gene transfer into neurons and glia in the brain, <i>Science</i> , 259 , 988-990, 1993	✓
62	LACOUR, S. et al., Anticancer agents sensitize tumor cells to tumor necrosis factor-related apoptosis-inducing ligand-mediated caspase-8 activation and apoptosis, <i>Cancer Res.</i> , 61 , 1645-1651, 2001	✓
63	LEVERKUS, M. et al., Regulation of tumor necrosis factor-related apoptosis-inducing ligand sensitivity in primary and transformed human keratinocytes, <i>Cancer Res.</i> , 60 , 553-559, 2000	✓
64	LEVKAU, G. et al., xIAP induces cell-cycle arrest and activates nuclear factor-κB, <i>Circ. Res.</i> , 88 , 282-290, 2001	✓
65	LI, H. et al., Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis, <i>Cell</i> , 94 , 491-501, 1998	✓
66	LI, X. et al., Adenovirus-mediated Bax overexpression for the induction of therapeutic apoptosis in prostate cancer, <i>Cancer Res.</i> , 61 , 186-191, 2001	✓
67	LI, X. et al., Overexpression of BCL-X _L underlies the molecular basis for resistance to staurosporine-induced apoptosis in PC3 cells, <i>Cancer Res.</i> , 61 , 1699-1706, 2001	✓
68	LIN, J. et al., The phosphatidylinositol 3'-kinase pathway is a dominant growth factor-activated cell survival pathway in LNCaP human prostate carcinoma cells, <i>Cancer Res.</i> , 59 , (2891-2897), 1999	✓
69	LIN, Y. et al., The death domain kinase RIP is essential for TRAIL (Apo2L)-induced activation of IκB kinase and c-Jun N-terminal kinase, <i>Mol. Cell. Biol.</i> , 20 , 6638-6645, 2000	✓
70	LINJA, M. J. et al., Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer, <i>Cancer Res.</i> , 61 , 3350-3555, 2001	✓
71	LINDZEY, J. et al., Molecular mechanisms of androgen action, In <i>Vitamins</i>	✓



Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449APTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 6 of 9

Complete if Known

Application Number	10/077,435
Filing Date	February 15, 2002
First Named Inventor	M. Vijay Kumar
Group Art Unit	1614
Examiner Name	Unassigned
Attorney Docket Number	M0351-268908
Express Mail Certificate	EV 032 196 839 US

RECEIVED
NOV 14 2002
TECH CENTER 1600/2900

		and Hormones, Academic Press, G. Litwack Ed., Vol. 49, 383-432, 1994	
72	LUCCI, A. et al., Modification of ceramide metabolism increases cancer cell sensitivity to cytotoxics, <i>Intl. J. Oncol.</i> , 15 , 541-546, 1999		✓
73	MARCELLI, M. et al., Caspase-7 is activated during lovastatin-induced apoptosis of the prostate cancer cell line LNCaP, <i>Cancer Res.</i> , 58 , 76-83, 1998		✓
74	MARCELLI, M. et al., Signaling pathway activated during apoptosis of the prostate cancer cell lines LNCaP: Overexpression of caspase-7 as a new gene therapy strategy for prostate cancer, <i>Cancer Res.</i> , 59 , 398-406, 1999		✓
75	MARCELLI, M. et al., Heterogenous apoptotic responses of prostate cancer cell lines identify an association between sensitivity to starosporine-induced apoptosis, expression of Bcl-2 family members and caspase activation, <i>Prostate</i> , 42 , 260-273, 2000		✓
76	MARSTERS, S. A. et al., Activation of apoptosis by Apo-2 ligand is independent of FADD but blocked by CrmA, <i>Curr. Biol.</i> , 6 , 750-752, 1996		✓
77	MARTINO, J. C. et al., Breaking the mitochondrial barrier, <i>Nat. Rev. Mol. Cell Biol.</i> , 2 , 63-67, 2001		✓
78	MAYO, M. W. et al., The transcription factor NF-κB: control of oncogenesis and cancer therapy resistance, <i>Biochim. Biophys. Acta</i> , 1470 , M55-M62, 2000		✓
79	MICHNA, H. et al., Antitumor activity of the antiprogesterins ZK98.299 and RU 38.486 in hormone dependent rat and mouse mammary tumors: Mechanistic studies, <i>Breast Can. Res. Treat.</i> , 14 , 275-288, 1989		✓
80	MICHNA, H. et al., Progesterone antagonists block the growth of experimental mammary tumors in G ₀ G ₁ , <i>Breast Can. Res. Treat.</i> , 17 , 155-156, 1990		✓
81	MILLIKAN, R. E., Chemotherapy of advanced prostatic carcinoma, <i>Seminars Oncol.</i> , 26 , 185-191, 1999		✓
82	MORISHITA, R. et al., <i>In vivo</i> transfection of cis element "decoy" against nuclear factor-κB binding site prevents myocardial infarction, <i>Nature Med.</i> , 3 , 894-899, 1997		✓
83	NAGAKI, M. et al., Tumor necrosis factor α prevents tumor necrosis factor receptor-mediated mouse hepatocyte apoptosis, but not fas-mediated apoptosis: role of nuclear factor-κB, <i>Hepatology</i> , 32 , 1272-1279, 2000		✓
84	NAGANE, M. et al., Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor related apoptosis-inducing ligand <i>in vitro</i> and <i>in vivo</i> , <i>Cancer Res.</i> , 60 847-853, 2000		✓
85	NESTEROV, A. et al., Elevated Akt activity protects the prostate cancer cell line LNCaP from TRAIL-induced apoptosis, <i>J. Biol. Chem.</i> , 276 , 10767-10774, 2001		✓
86	NICHOLSON, D. W., From bench to clinic with apoptosis-based therapeutic agents, <i>Nature</i> , 407 , 810-816		✓
87	NIMMANAPALLI, R. et al., Pretreatment with paclitaxel enhances Apo-2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of prostate cancer cells by inducing death receptors 4 and 5 protein levels, <i>Cancer Res.</i> , 61 , 759-763, 2001		✓

Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449APTO



INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 7 of 9

Complete if Known

Applicati n Number	10/077,435
Filing Date	February 15, 2002
First Named Inventor	M. Vijay Kumar
Group Art Unit	1614
Examiner Name	Unassigned
Attorney Docket Number	M0351-268908
Express Mail Certificate	EV 032 196 839 US



88	NISHINO, Y. et al., Enhancement of the antitumor efficacy of the antiprogesterin, onapristone, by combination with the antiestrogen, ICI164384, <i>J. Can. Res. Clin. Oncol.</i> , 120 , 298-302, 1990	✓
89	OGASAWARA, J. et al., Lethal effect of the anti-Fas antibody in mice, <i>Nature</i> , 365 , 568-570, 1993	✓
90	OLSEN, N. J. et al., Androgens accelerate thymocyte apoptosis, <i>Endocr.</i> , 139 , 748-752, 1998	✓
91	PALVIMO, J. J. et al., Mutual transcriptional interference between RelA and androgen receptor, <i>J. Biol. Chem.</i> , 271 , 24151-24156, 1996	✓
92	PAN, G. et al., The receptor for the cytotoxic ligand TRAIL, <i>Science</i> , 276 , 111-113, 1997a	✓
93	PAN, G. et al., An antagonist decoy receptor and a death domain-containing receptor for TRAIL, <i>Science</i> , 277 , 815-818, 1997	✓
94	PAYEN, L. et al., Reversal of MRP-mediated multidrug resistance in human lung cancer cells by the antiprogesterin drug RU486, <i>Biochem. Biophys. Res. Comm.</i> , 258 , 513-518, 1999	✓
95	PERLMAN, H. et al., An elevated bax/bcl2 ration corresponds with the onset of prostate epithelial cell apoptosis, <i>Cell Death Differentiation</i> , 6 , 48-54, 1999	✓
96	PERRAULT, D. et al., Phase II study of the progesterone antagonist Mifepristone in patients with untreated metastatic breast carcinoma: A National Cancer Institute of Canada clinical trails groud study, <i>J. Clin. Oncol.</i> , 14 , 2709-2712, 1996	✓
97	PITTI, R. M. et al., Induction of apoptosis by Apo-2 Ligand, a new member of the tumor necrosis factor receptor family, <i>J. Biol. Chem.</i> , 271 , 12687-12690, 1996	✓
98	RASPER, D. M. et al., Cell death attenuation by "Usurpin", a mammalian DED-caspase homologue that precludes caspase-8 recruitment and activation by the CD-95 (Fas, APO-1) receptor complex, <i>Cell Death Differ.</i> , 5 , 271-288, 1998	✓
99	RAVI, R., Regulation of death receptor expression and TRAIL/Apo2L-induced apoptosis by NF-κB, <i>Nature Cell Biol.</i> , 3 , 409-416, 2001	✓
100	REED, J. C., Mechanisms of apoptosis, <i>Amer. J. Pathol.</i> , 157 , 1415-1430, 2000	✓
101	RICH, Development and analysis of recombinant adenoviruses for gene therapy of cystic fibrosis, <i>Human GeneTherapy</i> , 4 , 461-476, 1993	✓
102	RIPPLE, G. H. et al., Drug development in prostate cancer, <i>Seminar Oncol.</i> , 26 , 217-226, 1999	✓
103	ROCERETO, T. F. et al., Phase II study of Mifepristone (RU486) in refractory ovarian cancer, <i>Gynecol. Oncol.</i> , 77 , 429-432, 2000	✓
104	SANTEN, R. J., Endocrine treatment of prostate cancer, <i>J. Clin.Endocrinol. Metab.</i> , 75 , 685-689, 1992	✓
105	SCHNEIDER, C. C. et al., Inhibition of endometrial cancer cell lines by mifepristone (RU 486), <i>J. Soc. Gynecol. Invest.</i> , 5 , 334-338, 1998	✓
106	SCHNEIDER, M. R. et al., Antitumor activity of the progesterone antagonists ZK98.299 and RU 38.486 in the hormone-dependent MXT-mammary tumor model of the mouse and the DMBA- and the MNU-induced	✓

Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449APTO


INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 8 of 9

Compleat if Known

Applicati n Number	10/077,435
Filing Date	February 15, 2002
First Named Inv ntor	M. Vijay Kumar
Group Art Unit	1614
Examiner Name	Unassigned
Attorney Docket Number	M0351-268908
Express Mail Certificate	EV 032 196 839 US



RECEIVED
NOV 14 2002
TECH CENTER 1600/2900

		mammary tumor models of the rat, <i>Eur. J. Cancer Clin. Oncol.</i> , 25 , 691-701, 1989	
	107	SCHNEIDER, M. R. et al., Antitumor activity and mechanism of action of different antiprogestins in experimental breast cancer models, <i>J. Steroid Biochem. Mol. Biol.</i> , 37 , 783-787, 1990	✓
	108	SCHNEIDER, P. et al., TRAIL receptors 1 (DR4) and 2 (DR5) signal FADD-dependent apoptosis and activate NF-κB, <i>Immunity</i> , 7 , 831-836, 1997	✓
	109	SEOL, D-W. et al., Signaling events triggered by tumor necrosis factor-related apoptosis-inducing ligand (TRAIL): Caspase-8 is required for TRAIL-induced apoptosis, <i>Cancer Res.</i> , 61 , 1138-1143, 2001	✓
	110	SHEN, R. et al., Androgen-induced growth inhibition of androgen receptor expressing androgen-independent prostate cancer cells is mediated by increased levels of neutral endopeptidase, <i>Endocrinology</i> , 141 , 1699-1704, 2000	✓
	111	SHERIDAN, J. P. et al., Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors, <i>Science</i> , 277 , 818-821, 1997	✓
	112	SRIDHAR, S. et al., Differential expression of members of the tumor necrosis factor α-related apoptosis-inducing ligand pathway in prostate cancer cells, <i>Cancer Res.</i> , 61 , 7179-7183, 2001	✓
	113	SUGIYAMA, H. J. et al., Selective sensitization to tumor necrosis factor-α-induced apoptosis by blockade of NF-κB in primary glomerular mesangial cells, <i>Biol. Chem.</i> , 274 , 19532-19537, 1999	✓
	114	SUZUKI, Y. et al., X-linked inhibitor of apoptosis protein (XIAP) inhibits caspase-3 and-7 in distinct modes, <i>J. Biol. Chem.</i> , 276 , 27058-27063, 2001	✓
	115	TENNISWOOD, M. et al., Apoptosis in hormone-dependent cancers, <i>Ernst Schering Research Foundation Workshop</i> , 14 , Springer-Verlag, Berlin Heidelberg, 1995	✓
	116	UMEKITA, Y. et al., Human prostate tumor growth in athymic mice: inhibition by androgens and stimulation by finasteride, <i>Proc. Natl. Acad. Sci., USA</i> , 93 , 11802-11807, 1996	✓
	117	VAN ANTWERP, D. J. et al., Suppression of TNF-α-induced apoptosis by NF-κB, <i>Science</i> , 274 , 787-789, 1996	✓
	118	VAN ANTWERP, D. J. et al., Inhibition of TNF-induced apoptosis by NF-κB, <i>Trends Cell Biol.</i> , 8 , 107-111, 1998	✓
	119	VAN OPHOVEN, A. et al., Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) for treatment of prostate cancer: first results and a review of literature, <i>Prostate Cancer Prostatic Dis.</i> , 2 , 227-233, 1999	✓
	120	VLIESTSTRA, R. J. et al., Frequent incitivation of PTEN in prostate cancer cell lines and xenografts, <i>Cancer Res.</i> , 58 , 2720-2723, 1998	✓
	121	WALCZAK, H. et al., TRAIL-R2: A novel apoptosis-mediating receptor for TRAIL, <i>EMBO J.</i> , 16 , 5386-5397, 1997	✓
	122	WALCZAK, H. et al., Tumorcidal activity of tumor necrosis factor-related apoptosis-inducing ligand <i>in vivo</i> , <i>Nature Med.</i> , 5 , 157-163, 1999	✓
	123	WANG, C-Y et al., NF-κB induces expression of the Bcl-2 homologue A1/Bfl-1 to preferentially suppress chemotherapy-induced apoptosis, <i>Mol. Cell. Biol.</i> , 19 , 5923-5929, 1999	✓
	124	WANG, C-Y et al., NF-κB antiapoptosis: induction of TRAF1 and TRAF2	✓

Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449APTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 9 of 9

Complete if Known

Application Number	10/077,435
Filing Date	February 15, 2002
First Named Inventor	M. Vijay Kumar
Group Art Unit	1614
Examiner Name	Unassigned
Attorney Docket Number	M0351-268908
Express Mail Certificate	EV 032 196 839 US



		and c-IAP1 and c-IAP2 to suppress caspase 8 activation, <i>Science</i> , 281 , 1680-1683, 1998	
	125	WANG, J-D. et al., Early induction of apoptosis in androgen-independent prostate cancer cell line by FTY720 requires caspase-3 activation, <i>Prostate</i> , 40 , 50-55, 1999	✓
	126	YAMANAKA, T. et al., Chemotherapeutic agents augment TRAIL-induced apoptosis in human hepatocellular carcinoma cell lines, <i>Hepatology</i> , 32 , 482-490, 2000	✓
	127	YEH, W-C et al., Gene targeting in the analysis of mammalian apoptosis and TNF receptor superfamily signaling, <i>Immunol. Rev.</i> , 169 , 283-302, 1999	✓
	128	YU, R. et al., Tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in androgen-independent prostate cancer cells, <i>Cancer Res.</i> , 60 , 2384-2389, 2000	✓
	129	ZHANG, H. et al., Induction of apoptosis in prostatic tumor cell line DU 145 by staurosporine, a potent inhibitor of protein kinases, <i>Prostate</i> , 29 , 69-76, 1996	✓
	130	ZHANG, X. D. et al., Relation of TNF-related apoptosis-inducing ligand (TRAIL) receptor and FLICS-inhibitory protein expression to TRAIL-induced apoptosis of melanoma, <i>Cancer Res.</i> , 59 , 2747-2753, 1999	✓
	131	ZHAU, H.Y.E. et al., Androgen-repressed phenotype in human prostate cancer, <i>Proc. Natl. Acad. Sci., USA</i> , 93 , 15152-15157, 1996	✓
	132	ZONG, W. X. et al., The prosurvival Bcl-2 homolog Bfl-1/A1 is a direct transcriptional target of NF-κB that blocks TNFα-induced apoptosis, <i>Genes Dev.</i> , 13 , 382-387, 1999	✓
	133	ZOU, H. et al., An APAF-1 cytochrome c multimeric complex is a functional apoptosome that activates procaspase-9, <i>J. Biol. Chem.</i> , 274 , 11549-11556, 1999	✓

Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

+

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
M0351-268908
WINLIB01:949414.1